1 neonatal respiratoty distress. 2 3 signs&symptoms 1. intercostal retraction 2....
TRANSCRIPT
1
Neonatal Respiratoty
distress
2
3
Signs&symptoms
1. Intercostal retraction
2. tachypnea>60-80/minute
3. Grunting
4. cyanosis in room air; pao2<60minHg in fio2>0.4
5. Flaring of the ala nasi
6. reduced air exchange
7. Apnea
8. Stridor
1. Intercostal retraction
2. tachypnea>60-80/minute
3. Grunting
4. cyanosis in room air; pao2<60minHg in fio2>0.4
5. Flaring of the ala nasi
6. reduced air exchange
7. Apnea
8. Stridor
4
Downes, or RDS score
0 1 2Cyanosis None In room air In 40%FIO2
Retractions None Mild Severe
Grunting None Audible with stethoscope
Audible without stethoscope
Air entry Clear Decreased or delayed
Barely audible
Respiratory rate Under 60 60-80 Over 80 or apnea
Score:>4= Clinical respiratory distress; monitor arterial blood gases
>8=Impending respiratory failure
5
6
7
Normal ABG
Respiratory Failure
pao2> 55-80 mm Hg
paco2 > 35-40 mm Hg
PH= 7.35 – 7.40
pao2> 55-80 mm Hg
paco2 > 35-40 mm Hg
PH= 7.35 – 7.40
pao2 <50 mm Hg
paco2 >60 mm Hg
PH ≤ 7.2
pao2 <50 mm Hg
paco2 >60 mm Hg
PH ≤ 7.2
8
Evaluation: 1. History
2. Ph .E (Downes’or RDS score)
3. CHEST XRAY
4. BLOOD GLUCOSE
5. BLOOD CULTURE – CBC
6. ABG
7. ECHO , ECG
9
Respiratory distress syndrome(HMD)
•Disorder of premature infants
•Respiratory distress–tachypnea,grunting,flaring, retractions
10
• Difficult to distinguish from pneumonia
• Severity peaks at 24-48 hours, resolution by 72-96 hours (without surfactant therapy)
• Recovery prolonged by barotrauma or oxidative injury
11
12
Diagnosis
1. History Time of onset of signs
2. C.xray airbronchogram, reticular-granular patlern
13
14
15
Complications 1. Airleaks
2. Sepsis
3. IVH
4. PDA
5. BPD
6. ROP
16
Acute Complications
• Air Leak Syndromes–Consider with sudden change in
condition–More common if baby receiving
ventilatory support– Pneumothorax most common
• Therapy–None if stable–Oxygen 100%– Thorocentesis: Needle or tube
17
Acute Complications
• Intracranial Hemorrhage– High risk if HMD is severe– More common at lower gestational ages– Rare above 33 weeks gestation
• Suspect if there is a sudden change in condition
• May coincide with development of air leak• Signs: change in Fontanel, perfusion
18
Acute Complications
• Patent Ductus arteriosus–Usually evident during resolution
phase• Signs of Congestive Heart Failure– Increased oxygen need–Cardiomegaly–Acidosis, decreased urine output
• Therapy:–Decrease fluid intake– Indomethacin
19
Prevention:
• Prevention of permature birth• Prevent of cold strass , birth asphyxia and
hypovolemia• Administration of corticosteroids to the
mother at least 24-48 hours before delivery at gestatinl age< 34 weeks.
• Administration of surfactants in V.L.B.W
20
Treatment 1. Supportive care (treatment of acidosis,
Hypotension, Hypothermia) Decrease fluid Intake
2. Oxygen therapy (Pao2 = 66-70 mmHg Sao2>90%)(CpAp-Mecliancal Ventilution)
3. Surfactant Therapy
21
Initial Care
• Maintain warmth- cold stress will mimic other causes of distress
• Monitor blood glucose levels- assure they are normal
• Provide enough oxygen to keep the baby pink
22
Initial Care
Ensure adequate hydration:• Start fluids at 70-80 ml/kg/d 10% glucose
solution• Smaller babies may need more fluid• Add electrolytes by the second day
• On day 3-4 watch for diuresis
23
Initial Care
Consider other etiologies:• INFECTION,INFECTION
– Evaluate– Begin antibiotic therapy as prophylaxis– Continue as clinically indicated
• Anatomic malformations
24
Assess circulation
• Monitor heart rate• Assess Blood pressure• Check peripheral perfusion and capillary
refill• Avoid excessive blood sampling
25
Respiratory DISTRESS(NICU)Respiratory
RateFio2 Expiratory
Grunt Lowerchest Retraction
Xiphoid Retraction
0 60min <.30 None None None
1 60-80/min .30-.40 Stethoscope only
Just visible Just visible
2 >80min >040 Naked ear Marked Marked
If the score is <3 continue To observe. If the score is >4 insert an arterial line and monitor gasea. If the score is >6 consider CPAP. If the score is >8 consider mechanical ventilation.
26
CPAP Indications
• FiO2 above 0.3 with clinical distress
• FiO2 above 0.4
• Significant retractions after extubation• Hypoventilation: CPAP may be helpful
27
CPAP risks
• Hard to control in spontaneously breathing baby, especially if vigorous or close to term
• Potential for airleak• Can’t give surfactant• May rarely worsen ventilation
28
CPAP - Mechanism of action•CPAP prevents collapse of unstable alveoli
upon expiration
•Facilitates recruitment of unventilated alveoli
•Reduces right to left shunting across foramen ovale
•Reduces left to right shunting across the Ductus Arteriosus, improving cardiac output and blood pressure
29
Mechanical Ventilation• FiO2 more than 0.35 -0.4 on CPAP
• Early treatment if condition is deteriorating
• Decreasing “work of breathing”• Frequent apnea• Plan to give surfactant therapy• Absolutely: for prolonged apnea or
hypoxemia in absence of heart disease
30
Mechanical ventilation - risks
• May require sedation, reducing spontaneous respiration
• Airleaks , especially as compliance improves
• Baro-Volutrauma and risk of chronic lung injury
31
ExogenousSurfactant Preparations
•Alveofact*: bovine lung surfactantextract
•Curosurf: porcine lung surfactant extract, lipids
•Exosurf Neonatal*: colfosceril palmitate, cetyl alcohol, tyloxapol
• Infasurf: calf lung surfactant extract
•Survanta: bovine lung surfactant extract, lipids
*Not Available in USA
32
Functions of SurfactantAssociated Proteins
• Hydrophilic– SP-A: tubular myelin, host defense– SP-D: surfactant lipid homeostasis,
host defense, antioxidant
• Hydrophobic– SP-B: surface tension reduction,
tubular myelin, type II cell functions– SP-C: surface tension reduction,
film stabilityLeVine et al, 2001
33
Before SurfactantTreatment
45 MinutesPost-Treatment
Radiographic Changes WithExogenous Surfactant Treatment
34
Relationship of Antenatal Corticosteroidsand Postnatal Surfactant
Neonatal Mortality
Jobe et al, 1993
17.715.2
24.9
0.5
0
5
10
15
20
25
30
35
Maternal Corticosteroids No Maternal Corticosteroids
Mor
talit
y (%
)
Surfactant No Surfactant
**
**
57 46 555 566
35
Multi-Dose Studies Two-Year Follow-Up Survanta® (beractant)
Respiratory Complications
Survanta Multi-Dose Study Group, 1994
13.3
20.2
4.4
6.9
3
16
3.51.8
11.1
0.2
0
5
10
15
20
25
Allergies ReceivingBronchodilator
ReceivingOxygen
Wheezing Tachypnea
%
Control Survanta
**
**
201 226 201 225 202 226 203 226 203 226
36
Multi-Dose Studies Two-Year Follow-Up
Survanta® (beractant)CNS Complications
6.9 6.4
1.5
14.3
4.9 5.3
2.7
8.9
0
5
10
15
20
25
Hydrocephalus Shunt Seizures Cerebral Palsy
%
Control Survanta
201 226 201 226 201 226 201 226
Survanta Multi-Dose Study Group, 1994
37
Transien tachypnea of the Newborn(T.T.N)
Wet lung, RDSII, Mild HMD
38
• Delayed resorption of fetal lung fluid Risk Factors:
1- delayed in cord clamping2- c/s delivery 3- term- preterm neonates 4- the mother who received excessive fluid befor
delivery.
39
Signs & symptom
• Mild respiratory distress present at birth or a few hour after birth
• ABG Normal or mild hypoxia & Acidosis
40
C.XRay:•Overaeration , flat-
diaphragms, prominent pulmonary vacular marking sometimes fluid lines present in the fissures.
41
• Delayed resorption of fetal lung fluid
Most consider, and rule out pneumonia• Treat with antibiotics if diagnosis is
uncertain–Oxygen need beyond six hours–Oxygen need increasing–Worsening symptoms
42
• Patients usually recover rapidly between 3-5 days
• Treatment= supportive therapy.
43
44
MECONIUM ASPIRATION SYNDROME (MAS)
45
Approximately 13% of All live births are complicated by MSAF5% of MSAFMAS
46
MSAF>Term, post term, IUGRMSAF< Preterm <34 weeks
47
Risk factors for meconium- stained amniotic fluid
• Maternal hypertension • Maternal diabetes mellitus • Maternal heavy cigarette smoking• Maternal chronic respiratory or
cardiovascular disease• Postterm pregnancy• Pre-eclampsia/ eclampsia
48
(cont.)•Oligohydramnios• Intrauterine growth retardation •Poor biophysical profile •Abnormal fetal heart rate
patterns
49
•MAS
Mild Less than 40% O2 < 48H
Moderate More thon 40% O2>48H No air leak
Severe Assisted ventilation >48 PPHN
50
Mechanism of injure:
1. Obstruction of air ways
2. Chemical pneumonitis
3. Vasoconstriction of pulmonary vessels
4. Inactivation of surfactant
51
52
53
54
55
56
57
Management :
1. Fetal heart rate monitoring (Fetal Pulse oximetry)
2. Amnioinfusion
3. Intrapartum suctioning
58
Meconium Present?
Suction mouth, nose, and posterior pharynx after delivery of head, but before delivery of shoulders
Baby vigorous?*
Suction mouth and trachea
Continue with remainder of Initial steps:
Clear mouth and nose of secretions
Dry, stimulate, and reposition
Give O2 ( as necessary )
NO
NO
Yes
Yes
59
Treatment in NICU:
• Oxygen Therapy• Surfactant Therapy• Inhaled Nitric oxide • ECMO
60
61
پنومونی در نوزادان
شايع ترين علت HMDپنومونی بعد از ديسترسی تنفسی می باشد و
شامل :
I پنومونی مادر زادی و داخل -رحمی
II – پنومونی موقع تولد يا آسپيراسيون
III پنومونی بعد از تولد -
62
-Iپنومونی مادر زادی
راه انتقال از طريق جفت می باشد .
عامل بيماريزا : عفونت های مادر ( ، ترپونما پاليدوم TORCHزادی )
) ادنو مايکوپالسما و گاها ويروس ها می ويروس ها و آنترو ويروس ها (
باشند
63
عالئم
در ساعت های اول پس از تولد •ظاهر ميشود .
عالوه بر گرفتاری ريه ، گرفتاری در • –ساير احشاء نظير بزرگی کبد
طحال ، تظاهرات جلدی )پتشی( و اختالالت عصبی موجود است .
نوزادان يا مرده متولد ميشوند و يا در •عرض چند ساعت اول حيات فوت می
کنند .
64
II – پنومونی موقع تولد يا آسپراسيون
راه انتقال کانال زايمان می باشد . عامل بيماريزا : ميکروبهای موجود
، GBSدر کانال زايمانی : نظير E.coli . می باشند .... ،
65
عالئم :ظهور عالئم از چند ساعت تا چند
روز پس از تولد متغيراست و می باشد .HMDبيشتر شبيه به
عوامل مساعد کننده : ، زايمان PROMپرماچوريتی ،
مشکل می باشند
66
III – : پنومونی بعد از تولد
راه انتقال : تماس با افراد آلوده و يا وسائل آلوده در بخش نوزادان می
باشد .
C.O.N.S ، C.O.P.Sعامل بيماريزا : اکثرا ( ، قارچ ها RSVو گاها ويروس ها )
) پس از اقامت زياد در بخش ( و کالمد يا می باشند .
عالئم : ظهور عالئم در خالل ماه اول حيات می باشد
67
: تشخيص
شرح حال •عالئم بالينی •آزمايشگاهی •گرافی قفسه صدری •
68
: درمانI – پنومونی قبل از هفته اول حيات آمپی
سيلين يا پنی سيلين + يک آمينوگليکوزيد II – پنومونی بعد از هفته اول حيات متی سيلين
يا وانکوماسين + يک آمينوگليکوزيد يا سفالوسپرين نسل سوم
III – پنومونی کالمديائی ارتيرومايسين يا تری سولفامتوکسازول –متوپريم
3-4طول مدت درمان ، در پنومونی استافيلوکوکی روز است.14-10 در ساير جرم ها –هفته
69